AFT Pharmaceuticals expects to break even this year despite launch delays

AFT Pharmaceuticals expects to break even this year despite launch delays
Rebecca Howard
By Rebecca Howard Aug. 3 (BusinessDesk) -  AFT Pharmaceuticals, which makes the Maxigesic painkiller, continues to target reaching breakeven by the end of this financial year regardless of whether it obtains any additional licensing income.  In the last financial year to the end of March, its loss narrowed to $12.7 million from $18.4 million, Chair David Flacks told shareholders at the annual general meeting in Auckland today that Maxigesic is now licensed in 125 countries – up from 110 at the end of its 2017 financial year – and the c...